Glioblastoma Multiforme
Content writer – Clinical
August 19, 2022
Summary "Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells."
Glioblastoma multiforme (GBM), the most aggressive brain cancer, recurs due to the resistance of glioblastoma stem cells (GSCs) to all standard therapies. This dismal therapy outcome has sparked intense...
Content writer – Clinical
August 05, 2022
Summary "Slowing down glioma growth by knocking out miR-21 in mice models."
Glioblastoma multiforme (GBM) is an aggressive form of glioma with a median survival of 15 months. Heterogeneity is one of the main characteristics of GBM. The tumor cells show variability not only from one patient...
Content writer – Clinical
July 29, 2022
Summary "Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma."
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain cancer in adults. It accounts for about 60-70% of gliomas. The standard treatment regimen for GBM is tumor resection followed...
Jr. scientist – Omics
July 15, 2022
Summary "Multifunctional silica-coated mixed polymeric micelles for integrin-targeted therapy of pediatric patient-derived glioblastoma."
Glioblastoma (GBM) is the malignant brain tumor of the primary central nervous system (CNS) arising from the glial cells having an incidence ranging from 5 to 8 persons per 100,000 individuals...
Sr. scientist - Omics
June 29, 2022
Summary "A phase Ib-IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma- CUSP9v3-2021."
Glioblastoma is the most common and aggressive primary malignant brain tumor in adults. Despite therapeutic interventions, glioblastoma prognosis remains very poor as most patients die…
Sr. scientist – Omics
June 24, 2022
Summary "Identification of new genetic clusters in glioblastoma multiforme: EGFR status and ADD3 losses influence prognosis."
Glioblastoma (GB) multiforme, IDH wild-type (GB-IDHwt) is the most frequent brain tumor with poor survival rate. Glioblastoma with mutant IDH enzyme shows good prognosis. The highly genetic heterogeity is responsible…
Content writer – Clinical
June 16, 2022
Summary "Effects of metformin as an add-on therapy against glioblastoma: an old medicine for novel oncology therapeutics."
Medical research is focused on finding solutions through diligent and innovative platforms in the field of health and disease. Every published paper holds a stepping stone toward gaining knowledge…
